-
Product Insights
Orthopedic Bone Cement and Casting Materials Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Orthopedic Bone Cement and Casting Materials Pipeline Market Report Overview Bone cement and casting materials are used to fix bone fractures or as a complement to other devices in procedures such as joint reconstruction and trauma fixation. The Orthopedic Bone Cement and Casting Materials pipeline market research report provides comprehensive information about the Orthopedic Bone Cement and Casting Materials pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials that...
-
Analyst Opinions
Development of Tele-remote and Autonomous Equipment in the Global Underground Mining Sector, 2023 Update
This report provides an analysis of the LHDs and underground mining trucks operating tele-remote control and autonomous systems. It includes machines sold with these systems as well as those retrofitted, for example by automation providers such as RCT and Nautilus. The total population of tele-remote control and autonomous underground mining trucks and LHDs is estimated at just over 1,000 including both autonomous-ready equipment as well as those operating autonomously. Of this, over half is in Australia and Canada, combined, with...
-
Company Profile
Rubius Therapeutics Inc – Company Profile
Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company. It focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company's RCT pipeline products comprise of RTX-240, RTX-321 aAPC, RTX-224, RTX-aAPC, and RTX-T1D. Its products under development are intended for the treatment of human papillomavirus 16-positive cancers, non-small cell lung cancer, type 1 diabetes, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer. The company also offers...
Add to Basket -
Company Profile
RepliCel Life Sciences Inc – Company Profile
RepliCel Life Sciences Inc (RepliCel) is a regenerative medicine company that develops autologous cell therapies to treat conditions caused by a deficit of healthy cells required for normal healing. The company’s pipeline products RCT-01, RCS-01 and RCH-01 cell therapies are designed to treat chronic tendinosis, UV-damaged, or aged skin and pattern baldness. It also develops a proprietary, next-generation injection device for delivery of its RCH-01 and RCS-01 products, which also has use with other dermatological injection procedures. The company works...
Add to Basket -
Product Insights
Hip Reconstruction Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Hip Reconstruction Pipeline Market Overview Hip reconstruction or hip replacement is a procedure that involves the replacement of the damaged or diseased parts of the hip joint. This category includes devices (implants) used in hip replacement procedures. The hip reconstruction pipeline market research report provides comprehensive information about the hip reconstruction pipeline reconstruction with a comparative analysis of the reconstruction at various stages of development and information about the clinical trials which are in progress. Key Segments ·      Primary Hip...
-
Product Insights
Net Present Value Model: Tai’ai
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Tai'ai Drug Details Telitacicept (Tai' ai)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – telitacicept
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry telitacicept Drug Details Telitacicept (Tai' ai) is a potential new TACI-Fc fusion protein, acts...
-
Thematic Analysis
Big Data in Pharmaceuticals – Thematic Research
The global data and analytics market in the pharma sector was valued at $1.4 billion in 2020. The healthcare and pharmaceutical industries generate data in abundance from a multitude of sources including physician notes, pathology reports, electronic health records (EHR), patient registries, genomics, clinical trials, social media, wearable devices, and many more. The dataset in question is huge in both size and complexity, rendering traditional data management techniques inefficient for processing. This big data in pharmaceuticals - thematic research report...
-
Product Insights
Spinal Cord Stimulators (SCS) – Medical Devices Pipeline Assessment, 2020
SCS is a device that comprises a surgically-implanted electrical pacemaker and electrodes that connect to the spinal cord to treat chronic pain disorders. GlobalData's Medical Devices sector report, “Spinal Cord Stimulators (SCS)-Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Spinal Cord Stimulators (SCS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Spinal Cord Stimulators (SCS) Pipeline Assessment report provides key information and...
-
Sector Analysis
OpportunityAnalyzer: Clostridium difficile Infections – Opportunity Analysis and Forecasts to 2026
Clostridium difficile, a Gram-positive, spore-forming, toxin-producing, non-invasive, anaerobic bacterium, is the causative organism of C. difficile infection (CDI), which is commonly associated with colitis, as well as C. difficile-associated diarrhea (CDAD. CDIs begin with colonization of the intestinal tract with C. difficile through community-acquired or healthcare-associated means. Observed most frequently in healthcare settings, CDIs often occur when normal intestinal flora are disrupted by antibiotic administration, which can give C. difficile a competitive growth advantage if patients are exposed to the...